Bayer's stock price fell to its lowest in nearly 7 years this week, in the wake of a third U.S. jury verdict that found its Roundup weedkiller caused cancer. The plaintiffs were awarded more than $2 billion, the 8th-largest product-defect jury award in U.S. history.
The bottom line: Bayer has lost more than 45% of its equity value since the merger with Monsanto, the maker of Roundup, for which it paid $66 billion. Bayer chose to do away with the Monsanto name and carry products like Roundup under its moniker.
Go deeper: Bayer to appeal latest verdict in Roundup weedkiller cancer claim